Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Keratosis, Actinic 12Head and Neck Neoplasms 3Condylomata Acuminata 3Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Exanthema 2Colorectal Neoplasms 2Breast Neoplasms 2Wounds and Injuries 1Warts 1Virus Diseases 1Usual Type Vulval Intraepithelial Neoplasia (uVIN) 1Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Squamous Intraepithelial Lesions 1Skin Neoplasms 1Sexually Transmitted Diseases 1Radiodermatitis 1Parapsoriasis 1Papillomavirus Infections 1Non-Muscle Invasive Bladder Neoplasms 1Non-Melanoma Skin Cancers 1Lymphoma, Follicular 1Keratosis, Seborrheic 1Hypogonadism 1Hemangioma, Cavernous 1Hemangioma 1

Interventions

Rituximab 295Cyclophosphamide 240Peripheral Blood Stem Cell Transplantation 114fludarabine phosphate 110Filgrastim 93Etoposide 85Radiotherapy 81Lenalidomide 79Vincristine 78Prednisone 77Mycophenolic Acid 66Doxorubicin 61Cyclosporine 59Whole-Body Irradiation 58Bendamustine Hydrochloride 58Melphalan 57Tacrolimus 53Busulfan 51fludarabine 50Cytarabine 48obinutuzumab 46Methotrexate 45Antilymphocyte Serum 43Bortezomib 42Methylprednisolone 37Carmustine 37sargramostim 36ibritumomab tiuxetan 32ibrutinib 30Dexamethasone 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lymphoma, Follicular × Gels × Clear all
NCT02796066 2017-04-26

TSN2898-201 Safety and Efficacy of TSN2898 in the Treatment of Acne Vulgaris

Thesan Pharmaceuticals, Inc.

Phase 2 Withdrawn
Lymphoid

Acne Vulgaris, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡